NRG and Pallas of the Netherlands intend to announce a detailed proposal this spring for working together as a single organisation in the development and production of nuclear medicines, and construction of a new research reactor, Petten-based NRG said.

Bertholt Leeftink, a former official in the Dutch government who was appointed chief executive officer of both NRG and Pallas June 2020, said that by combining forces the two organisations will be able to make “large steps forward in the development and production of nuclear medicines used for diagnostic purposes and for the treatment of patients suffering from life-threatening diseases”.

“To this end, we need to establish a state-of-the art infrastructure that is being developed as we speak,” he added.